In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...

Hemolytic anemia occurs when red blood cells are destroyed faster than they can be replaced. The loss of red blood cells ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

ZUG, Switzerland and BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

The Hong Kong-based developer of treatments for cancer and immunological diseases said the trial in adults with warm antibody autoimmune hemolytic anaemia [wAIHA] in China met its primary endpoint of ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported Monday that its investigational CD19-targeting allogeneic CAR T therapy, zugocaptagene geleucel (zugo-cel), has demonstrated ...

-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...